Afatinib

• Background:

  Afatinib is a clinically useful kinase inhibitor approved for the treatment of non-small cell lung cancer. It is a potent and highly selective inhibitor of mutant and wild-type EGFR (IC50 = 0.5 nM) and HER2 (IC50 = 14 nM) .

• Conjugation:

  Unconjugated

• Buffer:

  Pale yellow solid

• Storage Conditions:

  -20°C